Printer Friendly

IVAX GETS FINAL APPROVAL FOR GENERIC HYPERTENSION TABLETS.

IVAX Corporation (AMEX:IVX), Miami, has received final approval for the company's Abbreviated New Drug Application (ANDA) for bisoprolol fumarate and hydrochlorothiazide tablets in 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg strengths from the United States Food and Drug Administration (FDA). Bisoprolol fumarate and hydrochlorothiazide tablets are indicated for the treatment of hypertension and are the generic equivalent of Lederle Laboratories' Ziac(R) tablets, which have U.S. sales in excess of $200 million. IVAX will market the product through its wholly owned subsidiary, Zenith Goldline Pharmaceuticals, Inc.

IVAX Corporation, headquartered in Miami, Florida, is a holding company with subsidiaries engaged in the research, development, manufacturing, and marketing of branded and generic pharmaceuticals and veterinary and diagnostic products in the U.S. and international markets.

For more information, call 305/575-6043 or visit http://www.ivax.com.
COPYRIGHT 2000 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Date:Nov 1, 2000
Words:147
Previous Article:BOSTON PROBES GETS PATENT FOR PNA PROBE TECHNOLOGY.
Next Article:INTEGRA GETS GRANT TO DEVELOP RGD TECHNOLOGY.
Topics:


Related Articles
FDA GIVES TENTATIVE APPROVAL FOR GENERIC VERSION OF PROZAC.
FAULDING TO MARKET ENALAPRILAT INJECTION/ENALAPRIL TABLETS.
IVAX GETS FINAL FDA APPROVAL FOR TAMOXIFEN ANDA.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |